Portland, OR/Vancouver, WA., Dec. 7, 2017 / AbSci, LLC.
AbSci, a global leader in breakthrough biomanufacturing technologies, today announced that it is further expanding its offices and laboratory facilities.
“We’ve seen a significant increase in partnership deal flow, which is a testament to the innovation and quality of work performed by our scientists,” said CEO and Founder, Sean McClain. “As a result, we continue to scale our scientific team as well as our facilities to keep up with demand.”
AbSci has continued to grow its staff across all departments. Notably, Tom Huang, PhD, joins AbSci as Director of Fermentation. In his most recent position as Associate Principal Scientist at Merck, Dr. Huang developed upstream processes for multiple biologic drugs using a variety of hosts, including mammalian cell culture and microbial fermentation. Dr. Huang, who holds a PhD in chemical engineering from Purdue University, also previously worked at Genencor, where he led a team of scientists that developed patented fermentation broth formulations and novel processes using engineered hosts.
Phil Barish, PhD, VP of Research and Operations said, “We’re thrilled about the continual influx of high caliber scientists joining our team. Their contributions have elevated our technology and accelerated process innovations both upstream and downstream.”
AbSci is a global leader in biomanufacturing technologies. The company’s SoluPro™ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes. AbSci’s unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry. For more information, please visit abscibio.com